Type I interferon upregulation and deregulation of genes involved in monopoiesis in chronic myelomonocytic leukemia.


Journal

Leukemia research
ISSN: 1873-5835
Titre abrégé: Leuk Res
Pays: England
ID NLM: 7706787

Informations de publication

Date de publication:
02 2021
Historique:
received: 21 12 2020
revised: 07 01 2021
accepted: 10 01 2021
pubmed: 1 2 2021
medline: 2 4 2021
entrez: 31 1 2021
Statut: ppublish

Résumé

Chronic myelomonocytic leukemia (CMML) is characterized by myelomonocytic bias and monocytic proliferation. Whether cell-intrinsic innate immune or inflammatory upregulation mediate disease pathogenesis and phenotype or whether the degree of aberrant monocytic differentiation influences outcomes remains unclear. We compared the transcriptomic features of bone marrow CD34+ cells from 19 patients with CMML and compared to healthy individuals. A total of 1495 genes had significantly differential expression in CMML (q<0.05, fold change>2), including 1271 genes that were significantly upregulated and 224 that were significantly downregulated in CMML. Top upregulated genes were associated with interferon (IFN) alpha and beta signaling, chemokine receptors, IFN gamma, G protein-coupled receptor ligand signaling, and genes involved in immunomodulatory interactions between lymphoid and non-lymphoid cells. Additionally, 6 gene sets were differentially upregulated and 139 were significantly downregulated in patients with myeloproliferative compared to myelodysplastic CMML. A total of 23 genes involved in regulation of monopoiesis were upregulated in CMML compared to healthy controls. We developed a prediction model using Cox regression including 3 of these genes, which differentiated patients into two prognostic subsets with distinct survival outcomes. This data warrants further evaluation of the roles and therapeutic potential of type I IFN signaling and monopoiesis in CMML.

Identifiants

pubmed: 33517186
pii: S0145-2126(21)00012-6
doi: 10.1016/j.leukres.2021.106511
pii:
doi:

Substances chimiques

Interferon Type I 0
Neoplasm Proteins 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

106511

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR003167
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM122775
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA140388
Pays : United States

Informations de copyright

Copyright © 2021. Published by Elsevier Ltd.

Auteurs

Guillermo Montalban-Bravo (G)

Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. Electronic address: gmontalban1@mdanderson.org.

Faezeh Darbaniyan (F)

Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Rashmi Kanagal-Shamanna (R)

Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Irene Ganan-Gomez (I)

Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Caleb A Class (CA)

Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States; Butler University, Indianapolis, IN, United States.

Koji Sasaki (K)

Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Kiran Naqvi (K)

Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Yue Wei (Y)

Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Hui Yang (H)

Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Kelly A Soltysiak (KA)

Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Kelly S Chien (KS)

Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Carlos Bueso-Ramos (C)

Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Kim-Anh Do (KA)

Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Hagop Kantarjian (H)

Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Guillermo Garcia-Manero (G)

Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH